The role of igf/igf-1r signaling in hepatocellular carcinomas: Stemness-related properties and drug resistance

Mai Huong Thi Ngo; Han Yin Jeng; Yung Che Kuo; Josephine Diony Nanda; Ageng Brahmadhi; Thai Yen Ling; Te Sheng Chang; Yen Hua Huang

doi:10.3390/ijms22041931

The role of igf/igf-1r signaling in hepatocellular carcinomas: Stemness-related properties and drug resistance

Mai Huong Thi Ngo, Han Yin Jeng, Yung Che Kuo, Josephine Diony Nanda, Ageng Brahmadhi, Thai Yen Ling, Te Sheng Chang, Yen Hua Huang

Research output: Contribution to journal › Review article › peer-review

53 Citations (Scopus)

Abstract

Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem cell pluripotency and differentiation to trigger cell proliferation, organ development, and tissue regeneration during embryonic development. Unbalanced IGF/IGF-1R signaling can promote cancer cell proliferation and activate cancer reprogramming in tumor tissues, especially in the liver. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia. Most patients with advanced HCC develop tyrosine kinase inhibitor (TKI)-refractoriness after receiving TKI treatment. Dysregulation of IGF/IGF-1R signaling in HCC may activate expression of cancer stemness that leads to TKI refractoriness and tumor recurrence. In this review, we summarize the evidence for dysregulated IGF/IGF-1R signaling especially in hepatitis B virus (HBV)-associated HCC. The regulation of cancer stemness expression and drug resistance will be highlighted. Current clinical treatments and potential therapies targeting IGF/IGF-1R signaling for the treatment of HCC will be discussed.

Original language	English
Article number	1931
Pages (from-to)	1-34
Number of pages	34
Journal	International journal of molecular sciences
Volume	22
Issue number	4
DOIs	https://doi.org/10.3390/ijms22041931
Publication status	Published - Feb 2 2021

Keywords

Cancer stemness
IGFs inhibitor
Insulin-like growth factor
Liver cancer
Targeting drug resistance

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms22041931

Cite this

@article{715e66a29a89430a98200da02ab1bab3,

title = "The role of igf/igf-1r signaling in hepatocellular carcinomas: Stemness-related properties and drug resistance",

abstract = "Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem cell pluripotency and differentiation to trigger cell proliferation, organ development, and tissue regeneration during embryonic development. Unbalanced IGF/IGF-1R signaling can promote cancer cell proliferation and activate cancer reprogramming in tumor tissues, especially in the liver. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia. Most patients with advanced HCC develop tyrosine kinase inhibitor (TKI)-refractoriness after receiving TKI treatment. Dysregulation of IGF/IGF-1R signaling in HCC may activate expression of cancer stemness that leads to TKI refractoriness and tumor recurrence. In this review, we summarize the evidence for dysregulated IGF/IGF-1R signaling especially in hepatitis B virus (HBV)-associated HCC. The regulation of cancer stemness expression and drug resistance will be highlighted. Current clinical treatments and potential therapies targeting IGF/IGF-1R signaling for the treatment of HCC will be discussed.",

keywords = "Cancer stemness, IGFs inhibitor, Insulin-like growth factor, Liver cancer, Targeting drug resistance",

author = "Ngo, {Mai Huong Thi} and Jeng, {Han Yin} and Kuo, {Yung Che} and Nanda, {Josephine Diony} and Ageng Brahmadhi and Ling, {Thai Yen} and Chang, {Te Sheng} and Huang, {Yen Hua}",

note = "Funding Information: Funding: This study is supported by research grants from Ministry of Science and Technology, Taiwan (Grant numbers: MOST105–2628-B-038-008-MY3, MOST106–3114-B-038-001, MOST107–2321-B-038-002, MOST107–2314-B-038-057, MOST107–2314-B-038-061, MOST108-2314-B-038-006, MOST108–2321-B-038-003, MOST 109-2314-B-038-135, MOST 109-2321-B-038-003, MOST 109-2320-B-002-068, and MOST 109-2314-B-182-025). Funding Information: Acknowledgments: We gratefully acknowledge the academic and science graphic illustration service provided by the Office of Research and Development at Taipei Medical University. We also gratefully acknowledge the English editing service from Anita Infante. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = feb,

day = "2",

doi = "10.3390/ijms22041931",

language = "English",

volume = "22",

pages = "1--34",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

TY - JOUR

T1 - The role of igf/igf-1r signaling in hepatocellular carcinomas

T2 - Stemness-related properties and drug resistance

AU - Ngo, Mai Huong Thi

AU - Jeng, Han Yin

AU - Kuo, Yung Che

AU - Nanda, Josephine Diony

AU - Brahmadhi, Ageng

AU - Ling, Thai Yen

AU - Chang, Te Sheng

AU - Huang, Yen Hua

N1 - Funding Information: Funding: This study is supported by research grants from Ministry of Science and Technology, Taiwan (Grant numbers: MOST105–2628-B-038-008-MY3, MOST106–3114-B-038-001, MOST107–2321-B-038-002, MOST107–2314-B-038-057, MOST107–2314-B-038-061, MOST108-2314-B-038-006, MOST108–2321-B-038-003, MOST 109-2314-B-038-135, MOST 109-2321-B-038-003, MOST 109-2320-B-002-068, and MOST 109-2314-B-182-025). Funding Information: Acknowledgments: We gratefully acknowledge the academic and science graphic illustration service provided by the Office of Research and Development at Taipei Medical University. We also gratefully acknowledge the English editing service from Anita Infante. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/2/2

Y1 - 2021/2/2

N2 - Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem cell pluripotency and differentiation to trigger cell proliferation, organ development, and tissue regeneration during embryonic development. Unbalanced IGF/IGF-1R signaling can promote cancer cell proliferation and activate cancer reprogramming in tumor tissues, especially in the liver. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia. Most patients with advanced HCC develop tyrosine kinase inhibitor (TKI)-refractoriness after receiving TKI treatment. Dysregulation of IGF/IGF-1R signaling in HCC may activate expression of cancer stemness that leads to TKI refractoriness and tumor recurrence. In this review, we summarize the evidence for dysregulated IGF/IGF-1R signaling especially in hepatitis B virus (HBV)-associated HCC. The regulation of cancer stemness expression and drug resistance will be highlighted. Current clinical treatments and potential therapies targeting IGF/IGF-1R signaling for the treatment of HCC will be discussed.

AB - Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem cell pluripotency and differentiation to trigger cell proliferation, organ development, and tissue regeneration during embryonic development. Unbalanced IGF/IGF-1R signaling can promote cancer cell proliferation and activate cancer reprogramming in tumor tissues, especially in the liver. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia. Most patients with advanced HCC develop tyrosine kinase inhibitor (TKI)-refractoriness after receiving TKI treatment. Dysregulation of IGF/IGF-1R signaling in HCC may activate expression of cancer stemness that leads to TKI refractoriness and tumor recurrence. In this review, we summarize the evidence for dysregulated IGF/IGF-1R signaling especially in hepatitis B virus (HBV)-associated HCC. The regulation of cancer stemness expression and drug resistance will be highlighted. Current clinical treatments and potential therapies targeting IGF/IGF-1R signaling for the treatment of HCC will be discussed.

KW - Cancer stemness

KW - IGFs inhibitor

KW - Insulin-like growth factor

KW - Liver cancer

KW - Targeting drug resistance

UR - http://www.scopus.com/inward/record.url?scp=85101003785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101003785&partnerID=8YFLogxK

U2 - 10.3390/ijms22041931

DO - 10.3390/ijms22041931

M3 - Review article

AN - SCOPUS:85101003785

SN - 1661-6596

VL - 22

SP - 1

EP - 34

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 4

M1 - 1931

ER -

The role of igf/igf-1r signaling in hepatocellular carcinomas: Stemness-related properties and drug resistance

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this